The global PEGylated proteins market size reached US$ 1.3 billion in 2023. The market is projected to reach US$ 2.8 billion by 2032, exhibiting a growth rate (CAGR) of 9.14% during 2023-2032. The increasing prevalence of chronic diseases, the widespread product utilization in cancer treatment, and the escalating number of product approvals for PEGylated proteins represent some of the key factors driving the market.
PEGylated proteins are biomolecules that have been modified by covalent conjugation with polyethylene glycol (PEG). It involves the PEGylation technique that improves the pharmacokinetic behavior of the medicine by altering the biological molecule's physical and chemical characteristics, such as its conformation, electrostatic binding, and hydrophobicity. PEGylated proteins are widely used in therapeutic applications, such as vaccines, hormone replacement therapy, genetic disorders, anemia, and blood clotting disorder. It is also used in various drugs for diseases, including kidney disease, multiple sclerosis, hemophilia, and cancers. PEGylated proteins help in the extension of half-life, increasing stability, solubility, and proteolytic protection, reducing renal excretion, immunogenicity, and toxicity, and enhancing the efficacy of drug delivery. Besides this, PEGylated proteins are non-toxic, water-soluble, hydrophilic, non-antigenic, and non-immunogenic.
2. What is the expected growth rate of the global PEGylated proteins market during 2024-2032?
3. What are the key factors driving the global PEGylated proteins market?
4. What has been the impact of COVID-19 on the global PEGylated proteins market?
5. What is the breakup of the global PEGylated proteins market based on the product?
6. What is the breakup of the global PEGylated proteins market based on the protein type?
7. What is the breakup of the global PEGylated proteins market based on the application?
8. What is the breakup of the global PEGylated proteins market based on the end user?
9. What are the key regions in the global PEGylated proteins market?
10. Who are the key players/companies in the global PEGylated proteins market?
PEGylated proteins are biomolecules that have been modified by covalent conjugation with polyethylene glycol (PEG). It involves the PEGylation technique that improves the pharmacokinetic behavior of the medicine by altering the biological molecule's physical and chemical characteristics, such as its conformation, electrostatic binding, and hydrophobicity. PEGylated proteins are widely used in therapeutic applications, such as vaccines, hormone replacement therapy, genetic disorders, anemia, and blood clotting disorder. It is also used in various drugs for diseases, including kidney disease, multiple sclerosis, hemophilia, and cancers. PEGylated proteins help in the extension of half-life, increasing stability, solubility, and proteolytic protection, reducing renal excretion, immunogenicity, and toxicity, and enhancing the efficacy of drug delivery. Besides this, PEGylated proteins are non-toxic, water-soluble, hydrophilic, non-antigenic, and non-immunogenic.
PEGylated Proteins Market Trends
The rising prevalence of chronic diseases, such as kidney ailments, autoimmune diseases, genetic disorders, hepatitis, and rheumatoid arthritis across the globe is one of the key factors driving the market growth. PEGylated proteins are widely used to treat inflammation, deliver corrective genes to cells, prevent blood clots, deliver growth hormones, and prevent the progression of chronic kidney disease. In line with this, the widespread product utilization in cancer treatment to deliver chemotherapy drugs directly to cancer cells and reduce the side effects on healthy cells is favoring the market growth. Apart from this, various improvements in the PEGylation technology, such as the development of new PEGylation methods that can produce smaller and more complex molecules, are providing an impetus to the market growth. Additionally, the widespread adoption of PEGylation to improve the stability and half-life of colony-stimulating factors (CSFs), making them more effective as therapeutic agents, is acting as another growth-inducing factor. Furthermore, the rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving its efficiency, is propelling the market growth. Other factors, including the increasing number of product approvals for PEGylated proteins, development in the field of biotechnology and molecular biology engineering, the integration of PEG molecules in biopharmaceuticals and the associated advantages, rising geriatric population, and the implementation of various government initiatives to increase regulatory standards in the pharmaceutical industry, are anticipated drive the market further toward growth.Key Market Segmentation:
The report provides an analysis of the key trends in each segment of the global PEGylated proteins market, along with forecasts at the global, regional, and country level from 2023-2032. The report has categorized the market based on product, protein type, application, and end user.Product Insights:
- Consumables
- PEGylation Reagents
- PEGylation Kits
- Services
Protein Type Insights:
- Colony Stimulating Factors
- Interferons
- Erythropoietin
- mAbs
- Recombinant Factor VII
- Others
Application Insights:
- Cancer Treatment
- Hepatitis
- Chronic Kidney Diseases
- Hemophilia
- Multiple Sclerosis
- Gastrointestinal Disorders
- Others
End User Insights:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global PEGylated proteins market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Biomatrik Inc., Creative PEGWorks, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio Inc., NOF America Corporation (NOF Corporation), Profacgen, Thermo Fisher Scientific Inc., etc.Key Questions Answered in This Report
1. How big is the global PEGylated proteins market?2. What is the expected growth rate of the global PEGylated proteins market during 2024-2032?
3. What are the key factors driving the global PEGylated proteins market?
4. What has been the impact of COVID-19 on the global PEGylated proteins market?
5. What is the breakup of the global PEGylated proteins market based on the product?
6. What is the breakup of the global PEGylated proteins market based on the protein type?
7. What is the breakup of the global PEGylated proteins market based on the application?
8. What is the breakup of the global PEGylated proteins market based on the end user?
9. What are the key regions in the global PEGylated proteins market?
10. Who are the key players/companies in the global PEGylated proteins market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global PEGylated Proteins Market
6 Market Breakup by Product
7 Market Breakup by Protein Type
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 Drivers, Restraints, and Opportunities
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abcam plc
- Biomatrik Inc.
- Creative PEGWorks
- Iris Biotech GmbH
- JenKem Technology USA Inc.
- Laysan Bio Inc.
- NOF America Corporation (NOF Corporation)
- Profacgen
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 144 |
| Published | January 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.3 Billion |
| Forecasted Market Value ( USD | $ 2.8 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
